UPDATE 2-Endo bolsters men's healthcare business with Auxilium deal
* Endo offers $33.25/share for Auxilium
* Auxilium terminates deal with QLT
* Auxilium shares rise as much as 11 pct to $33
* Endo shares down 5 pct (Adds analyst comments, background; updates shares)
By Ankur Banerjee
Oct 9 (Reuters) - Endo International Plc brought a successful end to its month-long pursuit of Auxilium Pharmaceuticals Inc, with the smaller rival choosing a sweetened offer over its agreement to buy Canadian eye-drug maker QLT Inc.
The $1.67 billion deal for Auxilium expands Endo's portfolio to include Xiaflex, which is approved to treat Peyronie's disease - a condition that causes painful erections - and Dupuytren's contracture, a disease that impairs a person's ability to use their fingers.
"Endo recognizes the value inherent to Xiaflex, given the drug's potential in multiple additional indications," Aegis Capital analyst Raghuram Selvaraju said in a note.
Auxilium's lead drug is also being evaluated for use in frozen shoulder syndrome - a condition characterized by stiffness and pain in the shoulder joint - and to smoothen cellulite, a condition that causes dimpling of the skin, especially on women's hips and thighs. Continued...